Background {#Sec1}
==========

Polycystic ovary syndrome (PCOS) is an endocrine disorder which affects approximately 5 to 18% of women in childbearing age depending on the study population and the diagnostic criteria \[[@CR1]\]. The syndrome is associated with ovulatory dysfunction, which can lead to menstrual cycle disruption including amenorrhea and oligomenorrhea increasing the incidence of infertility \[[@CR2]--[@CR4]\]. Additionally, in most cases PCOS show evidence of insulin resistance and hyperinsulinemia \[[@CR1]\].

The incidence of endometrial hyperplasia in PCOS women is significantly higher than in controls and may, in part, be the result of hyperestrogenic anovulation and persistent hyperinsulinemia \[[@CR5]\]. However, endometrial function in women with PCOS appears to differ significantly from that of normal endometrium, a difference that may predispose these patients to endometrial hyperplasia and carcinoma \[[@CR6], [@CR7]\].

Investigators have reported that in PCOS endometrial metabolism is altered, with local insulin resistance and increased growth factor content \[[@CR8]\]. Growth factors mediating inflammation, including cytokines not only affect endometrial epithelial proliferation, but may alter factors in the extracellular matrix (ECM), including the production and action of small leucine-rich proteoglycans (SLRPs) \[[@CR9], [@CR10]\]. These proteoglycans play an important role in tissue homeostasis and cell proliferation, and protect the endometrium against agents that induce excessive endometrial proliferation \[[@CR11]--[@CR14]\]. Decorin, a specific SLRP, induces cell cycle arrest by activating cyclin-dependent protein kinase inhibitor, decreasing the activity and abundance of multiple cyclins, activating pro-apoptotic pathways and upregulating p21 synthesis in human endometrial stromal cells \[[@CR14], [@CR15]\].

The increased risk of endometrial hyperplasia and malignancy in PCOS is believed to be due not only to the reduction in the cyclic effect of progesterone, leading to chronic estrogen exposure, but also to the abnormal production of a large number of growth factors, cytokines, and other elements mediating inflammation \[[@CR9], [@CR10]\]. These factors may alter factors in the ECM, including SRLPs. However, the content of SLRPs in the endometrium of PCOS is unknown. Therefore, we designed a pilot study to test the hypothesis that the content of SLRPs, including decorin, lumican, fibromodulin, and biglycan, in the endometrium of PCOS subjects is detectable, and abnormal, which may predispose these patients to the development of endometrial hyperplasia and malignancy.

Methods {#Sec2}
=======

Study subjects {#Sec3}
--------------

PCOS and control women were recruited from an outpatient reproductive endocrinology clinic at an academic tertiary medical care center (Gynecology Division, Clinics Hospital) from 2013 to 2015. We prospectively recruited all PCOS subjects first and then a match among controls was sought (i.e. ±4 kg/m^2^ in BMI, ±4 years in age, and similar race to the PCOS subject), either from a previously recruited pool of controls or, if no control with the needed parameters was so identified, then a new control was sought. This recruitment strategy yielded cohorts of PCOS and controls similar in number, mean BMI, mean age and race distribution.

### PCOS patients {#Sec4}

The diagnosis of PCOS was made in accordance with the Rotterdam 2003 criteria, and subjects were categorized by phenotype (phenotype A-D) \[[@CR16], [@CR17]\]. Clinical hyperandrogenism was established by the presence of hirsutism, determined by a modified Ferriman and Gallwey (mFG) score equal to or higher than 8.

### Control {#Sec5}

Controls were healthy women with confirmed fertility (having had at least one child previously), who had undergone tubal ligation and had a long-term history of menstrual cycles with regular intervals (25--35 days). These women were not using hormonal contraceptive methods.

All subjects (PCOS patients and control) were 20--35 years of age. Women who had causes of hyperandrogenism other than PCOS, anovulation which had been treated with hormones or other drugs in the 6 months prior to the study, systemic diseases, sexually transmitted diseases, uterine tumors, ovarian cysts or tumors, additional endocrine disorders, or using any hormones, including hormonally active herbal substances, statins, corticoids, or infertility drugs in the previous 6 months were excluded.

All participants of the study were subjected to a detailed history and physical examination, where height, weight, waist circumference (WC), hip circumference (HC), hirsutism by the mFG score, and a transvaginal ultrasound scan of the ovaries was obtained. Waist circumference was measured at the narrowest area between the last rib and the iliac crest, and HC at the most prominent point of the gluteal area.

This study was approved by the Research Ethics Committee of the Clinics Hospital, University of São Paulo School of Medicine (CEP 0164/09) and informed written consent was obtained from all subjects. The study was carried out from April 1, 2012 to August 31, 2015.

Endometrial sampling {#Sec6}
--------------------

Endometrial samples (amount was 1.3 ± 0.45 g) were obtained using the Pipelle de Cornier catheter (Laboratoire CCD, Paris, France). Participants in the PCOS group were generally anovulatory and their endometrial biopsies were performed randomly after a negative pregnancy (β-hCG) result. Biopsies in the control group were scheduled during cycle days eight to twelve of the menstrual cycle. The rationale for this schedule was to avoid the menstruation period and the periovulatory phase \[[@CR18]\].

Histological processing of the endometrial samples {#Sec7}
--------------------------------------------------

Endometrial samples were fixed for 24 h in 10% formaldehyde, dehydrated in increasing concentrations of ethyl alcohol, cleared in xylene, and then imbedded in paraffin. Paraffin-embedded samples were then cut into ten 3-μm sections per subject. Eight of these sections were stained for SLRPs by immunohistochemistry (see below), and the two remaining sections were stained with hematoxylin and eosin (H&E), to confirm the menstrual cycle phase (proliferative) using the criteria suggested by Noyes et al. \[[@CR19]\] (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Photomicrographs of the endometrium in the proliferative phase (**a, b,** and **c**) of the CONTROL and PCOS women (**d, e,** and **f**). Note thicker surface epithelium (EP) and gland (GL) as well as a higher concentration of leukocytes within the lamina propria of the endometrium of PCOS patients in **d** and **e** compared to **a** and **b** (*thin arrows*). Also note typical apoptosis in **d** and **e** (*thick arrows*) (\* mitotic figure). Staining with H.E. **d** = 200X, **b** and **e** = 400X, and **c** and **f** = 100X

Sections of endometrium were incubated with the primary antibody for detection of decorin (Abcam 175,404), lumican (Abcam 168,348), fibromodulin (Bioss 12,362), and biglycan (Bioss 7552R), incubated with a second antibody, namely chicken antirabbit immunoglobulin G (DakoCytomation, Glostrup, Denmark), and then incubated in 0.05% DAB (3,3′-diaminobenzidine) (Sigma Chemical Co). Negative controls were prepared by incubating the sections with rabbit nonspecific immunoglobulin fraction (DAKOCytomation) instead of the primary antibody and by staining the sections with hematoxylin for nucleous identification.

The images obtained were examined with optical microscope and digitally analyzed with the Carl Zeiss® AxioVision microscopy software (Rel. 4.6. Oberkochen, Baden-Württemberg).

Tissue homogenate preparation and Western blot analysis {#Sec8}
-------------------------------------------------------

Endometrial samples were homogenized, prepared, and sonicated in a buffer of 50 mM Tris-HCl, 150 mM NaCl, and 1% Triton-X pH 7.4 containing a complete protease inhibitor cocktail and PhosSTOP tablets (Roche Applied Science). Protein levels were determined by the Bradford assay and equalized prior to boiling in Laemmli buffer (Bio-Rad Laboratories, Hercules, CA, USA). To detect Gal-1 and MAPKs, protein extracts (40 μg per lane) were loaded onto a 15% SDS-PAGE together with appropriate molecular weight markers (Bio-Rad Laboratories) and transferred to ECL Hybond nitrocellulose membranes. Reversible protein staining of the membranes with 0.1% Ponceau-S in 5% acetic acid (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was performed to verify protein transfer.

Membranes were incubated for 15 min in 5% BSA in Tris-buffered saline (TBS) before the addition of the rabbit polyclonal antibodies anti-decorin (Abcam175404), anti-lumican (Abcam168348), anti-fibromodulin (Bioss-12362R), anti-biglycan (Bioss-7552R), and anti-β-actin (Bs-12362R), all of which were diluted 1:500 in TBS with 0.1% Tween 20 (antibodies were purchased from Santa Cruz Biotechnology). Incubation was followed by 15 min of washing with TBS and 60 min of incubation at room temperature with peroxidase-conjugated goat anti-rabbit IgG (1:1000; Thermo Fisher Scientific, Inc., Rockford, MI, USA). Membranes were again washed for 15 min with TBS. Immunoreactive proteins were detected using an enhanced Supersignal West Pico chemiluminescent substrate kit (Thermo Fisher Scientific).

After exposure of the blots in dark room the resulting x-ray film was developed, imaged and quantified using ImageJ software1.440 (<http://imagej.nih.gov/ij/> National Institutes of Health, Bethesda, MD, USA) to determine the relative expression (arbitrary units, AU) of SRPL/β-actin.

Hormonal assays {#Sec9}
---------------

The serum levels of thyroid-stimulating hormone (TSH), free thyroxine, follicle-stimulating hormone (FSH), lutein hormone (LH), total testosterone (TT), free testosterone (Tfree), androstenedione (A), cortisol, prolactin (PRL), dehydroepiandrosterone sulfate (DHEAS), 17α-hydroxyprogesterone (17-OHP), fasting insulin, fasting glucose, 2-h oral glucose tolerance test, β-human chorionic gonadotropin (β-hCG), and sex hormone-binding globulin (SHBG) were measured in both groups. Total testosterone levels were determined in triplicate using an electrochemiluminescence immunoassay (Testosterone II Cobas™ kit, Roche Diagnostics GmbH, Mannheim, Germany). The minimum detectable level of TT with this assay is 0.025 ng/ml and the main cross-reaction is with androstenedione (\< 2.5%). The intra assay coefficient of variation (CV) was 12.5% and the inter assay CV was 13.8%.

Statistical analysis {#Sec10}
--------------------

All measurements were assessed for normality using the Kolmogorov-Smirnov test. The unpaired Student t-test was used to compare the PCOS and CONTROL groups. Statistical analysis was performed using the GraphPad Prism software version 3.0 for Windows (GraphPad Software, San Diego, CA, USA). The data are presented as mean ± standard deviation (SD), and the significance level was set at *p* \< 0.05.

Results {#Sec11}
=======

A total of 20 women, aged 20 to 35 years, agreed to participate in this pilot study: a) 10 women with PCOS (PCOS), all phenotype A (hyperandrogenism either clinical and/or biochemical + ovulatory dysfunction + polycystic ovarian morphology), and b) 10 matched controls (CONTROL). The characteristics of these groups are depicted in Table [1](#Tab1){ref-type="table"}.Table 1Characteristics of participantsCONTROL (*n* = 10)PCOS (*n* = 10)*p*-valueAge, years28.6 ± 2.029.6 ± 1.2NSCaucasian, n56NSBMI, Kg/m^2^27.49 ± 2.4528.01 ± 3.19NSTT (ng/dL)35.9 ± 11.783.09 ± 24.8\< 0.05\*DHEAS (mg/mL)421.5 ± 52.1520.4 ± 82.1NSTSH (μUI/mL)2.8 ± 1.72.9 ± 1.6NSInsulin (μUI/mL)8.8 ± 2.915.5 ± 3.5\< 0.05\*Glucose (mg/dL)81.8 ± 8.689.2 ± 11.9NS17-OHP (mg/mL)17.3 ± 8.418.3 ± 7.4NSFSH (mUI/ml)5.0 ± 1.25.1 ± 1.1NSLH (mUI/ml)5.9 ± 2.99.5 ± 3.8\< 0.05\*PRL (ng/dl)10.8 (4.3--34.5)11.4 (4.2--33.5)NSA (ng/mL)2.2 ± 0.84.2 ± 1.3\< 0.05\*Tfree (pg/dl)1.7 ± 0.402.1 ± 1.0NSData are expressed as median and standard deviation; *BMI* Body mass index, *TT* total testosterone, *TSH* thyroid stimulating hormone, *Tfree* free testosterone, *A* androstenedione, *LH* lutein hormone, *FSH* follicle-stimulating hormone, *PRL* prolactin, *17-OHP* 17α-hydroxyprogesterone, *DHEAS* dehydroepiandrosterone sulfate, *NS* nonsignificant difference (*p* \> 0.05). \*Significance of *P*-value \<0.05

Morphological analysis of endometrial samples {#Sec12}
---------------------------------------------

Morphological analysis confirmed that in CONTROL endometrial tissue obtained was in the proliferative phase on days 8--12 of the menstrual cycle. Samples demonstrated a simple columnar epithelium lining and well-developed glands with cells in mitosis and endometrial stroma with several fibroblasts with an obvious elliptical nucleus, indicating intense cellular activity and synthesis of extracellular matrix components **(**Fig. [1](#Fig1){ref-type="fig"} **)**, which are normal findings in the proliferative phase of the menstrual cycle in ovulatory patients.

The endometrial tissue of PCOS subjects had the epithelial lining and the glands were thicker, and the endometrial stroma contained many leukocytes, consistent with excessive estrogenic action compared to CONTROL subjects \[[@CR20]\]. In some PCOS subjects epithelial cells with signs of apoptosis and well-developed endometrial stroma were observed (Fig. [1](#Fig1){ref-type="fig"}).

Immunohistochemical detection and comparison of SLRPs in the endometrium {#Sec13}
------------------------------------------------------------------------

Immunohistochemical analysis demonstrated SLRPs throughout the ECM of endometrial samples of both CONTROL and PCOS subjects. In both groups, SLRPs were also present throughout the endometrial stroma and could be observed clearly in the basement membrane of blood vessels, the epithelial lining, and the glands.

In CONTROL the intensity of immunoreactivity of biglycan and lumican was increased compared to that of decorin and fibromodulin. Alternatively, in PCOS biglycan, decorin, and lumican immunoreactivity were heightened compared with that of fibromodulin. Overall, the immunoreactivity pattern of SRPLs was higher in PCOS compared to CONTROL subjects (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Photomicrographs of the endometrium in the proliferative phase of CONTROL and PCOS women. Endometrial fragments subjected to immunohistochemical methods for identification of decorin, biglycan, lumican, and fibromodulin. Bar = 20 μm

Quantification of SLRP expression by Western blotting {#Sec14}
-----------------------------------------------------

The expression of each SRPL studied (i.e. decorin, lumican, fibromodulin, and biglycan) relative to that of β-actin is summarized in Table [2](#Tab2){ref-type="table"} and Fig. [3](#Fig3){ref-type="fig"}. Overall, decorin and lumican had higher relative expressions in the PCOS than in CONTROL subjects (*p* \< 0.05).Table 2SLRP content in endometrial stromal cells in PCOS and CONTROL subjects^a^Anti-decorinAnti-biglycanAnti-lumicanAnti-fibromodulinCONTROL3.4 ± 0.3\*\*17.5 ± 5.712.1 ± 0.5\*\*11.9 ± 2.7PCOS7.6 ± 0.521.1 ± 4.640.7 ± 0.415.1 ± 3.2^a^Western blotting yield relative to beta-actin values of the SLRPs studied (mean ± SD) in endometrial stromal cells. Data are expressed as median and standard deviation. \*\* Significance of *P*-value \<0.05 Fig. 3Western blotting results for decorin, lumican, biglycan, and fibromodulin expression in the endometrium of CONTROL and PCOS women

Discussion {#Sec15}
==========

Endometrial growth and differentiation is under the influence of sex hormones such as estrogen, progesterone, and androgens. In women with PCOS there is a deficiency in cyclic progesterone production due to chronic anovulation and a relative increase in other substances, such as insulin, cytokines, and growth factors, which results in an imbalance in endometrial hemostasis in these patients, possibly leading to abnormal uterine bleeding, infertility, and an increased risk of developing endometrial hyperplasia \[[@CR3], [@CR21]--[@CR25]\]. The specific receptors for insulin and Insulin Growth Factors (IGFs) as well as high-affinity IGF-binding proteins (IGFBPs) have been detected in endometrial tissues \[[@CR26]\]. IGFs have proliferative effects and the secretion of these IGFBPs, which can modulate the bioavailability of IGFs by competing with the IGF receptor, is stimulated by progesterone and inhibited by insulin. Consequently the action of IGFs may be more intense in endometrial cells \[[@CR6]\]. Moreover, both insulin and IGF-I inhibit the hepatic synthesis of sex-hormone binding globulin (SHBG) \[[@CR27]\], and insulin stimulates aromatase activity in both endometrial glands and stroma, thus enhancing endogenous endometrial estrogen production \[[@CR27], [@CR28]\]. The final result is an excess of estrogen and IGFs action on the endometrium of PCOS.

Furthermore, data on stromal (non-epithelial) structures in the endometrium of women with PCOS are lacking \[[@CR3], [@CR10], [@CR24], [@CR25]\]. Therefore, our pilot study has contributed to the scientific literature with the following two findings: a) demonstrating the presence of SLRPs in the endometrium of women with PCOS; and b) demonstrating that the SLRP content in these women appears to be abnormal, specifically appearing to be enhanced relative to normals.

Previous studies have reported that SRLPs in the endometrium are important for embryonic implantation and placentation \[[@CR24], [@CR29], [@CR30]\]. However, such studies have not included women with PCOS. In fact, the expression and distribution of endometrial decorin, biglycan, lumican, and fibromodulin are hormone dose dependent \[[@CR30]\]. The hyperandrogenism may explain the upregulated production of decorin and lumican. Under the influence of the ovarian hormones estrogen and progesterone, the endometrial SLRPs undergo profound changes during the menstrual cycle in normal women. However, we have not assayed the level of estrogen and progesterone at time of endometrial sampling. It is one limitation of our study.

Increased decorin and lumican in endometrial ECM may have a local antiproliferative activity due to bind cytokines and growth factors \[[@CR31], [@CR32]\]. Furthermore, some investigators suggest that decorin and lumican inhibit tumor growth, particularly in prostate and lung cancer \[[@CR33], [@CR34]\]. Thus, these SLRPs may partially protect the endometrium of women with PCOS from malignant transformation.

The mechanism of action of decorin and lumican includes blocking tyrosine kinase receptors (TKR) and reducing the influence of EGFR, IGF-IR, HGFR, and VEGFR-2 on the endometrium. Moreover, decorin restrains angiogenesis by binding to thrombospondin-1, TGFβ, VEGFR-2, and possibly IGF-IR, and then halting tumor growth by antagonizing oncogenic TKRs and angiogenesis \[[@CR35], [@CR36]\]. These effects may negatively act on the implantation process by inhibiting trophoblast migration and invasion \[[@CR36]\].

The collagen fiber is the most abundant component in the extracellular matrix. It is present in the ECM as a fibrillar protein providing structural support to cells and participating in cell-cell and cell-matrix interactions; thus, it has a fundamental role in tissue architecture \[[@CR37]--[@CR39]\]. Collagen fibers interact with extracellular matrix components, such as heparin sulfate. A research carried out by Giordano et al. \[[@CR40]\] demonstrate alterations in the endometrial glycosaminoglycan levels -- chiefly those of heparan sulfate -- in women with PCOS.

Conclusion {#Sec16}
==========

Notwithstanding the sex steroid disorder, the exact pathophysiological mechanisms of endometrial PCOS believed to account for excessive endometrial proliferation are not known \[[@CR41], [@CR42]\]. Our data suggests that the endometrium of patients with PCOS exhibits higher expressions of decorin and lumican than that of healthy control women in the proliferative phase of the menstrual cycle. It is then possible that this proteoglycan excess may interfere with normal endometrial hemostasis in PCOS. Further studies are warranted.
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